Increased FoxP3 and PD-L1 in non-pCR tissue from early stage HER2 positive breast cancer patients treated with trastuzumab-pertuzumab based regimens
| Autor: | Kimberly L. Blackwell, Lynn Howie, Rex C. Bentley, Smita K. Nair, Sara Abbott, Gloria Broadwater, Kelly E. Westbrook, Michelle Parks, Donna L. Topping, Paul K. Marcom, Jeremy Force, Gretchen Kimmick |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Tumor microenvironment Pathology biology business.industry FOXP3 medicine.disease Carboplatin chemistry.chemical_compound Breast cancer chemistry Trastuzumab Internal medicine PD-L1 medicine biology.protein Pertuzumab Stromal tumor skin and connective tissue diseases business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 34:602-602 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2016.34.15_suppl.602 |
| Popis: | 602Background: Increased stromal tumor infiltrating lymphocytes (STILs) may predict for pathologic complete response (pCR) in HER2+ breast cancer patients treated with neoadjuvant trastuzumab (H). Taxanes (T) and carboplatin (C) have immune modulating effects. Antibody-dependent cytotoxicity is a major mechanism of action of H, which may be enhanced by T, C, and pertuzumab (P). Pre and posttreatment tumor microenvironment immune markers in subjects treated with neoadjuvant HER2-targeted regimens have not been thoroughly described. This study quantifies baseline and changes in STILs, CD4+, CD8+, FoxP3+, and PD-L1+ cells in thirty HER2+ patients receiving neoadjuvant H-P regimens. Methods: Thirty patients with pre and post neoadjuvant TCH (n = 4) or TCHP (n = 26) tissue available were identified. STILs were measured manually by H&E. CD4, CD8, FoxP3, and PD-L1 were stained by immunohistochemistry (IHC). Immune infiltrates were compared between the pCR and non-pCR groups using the Wilcoxon rank sums test. The... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|